Stock listing
NASDAQ:PMCB PharmaCyte Biotech, Inc. Stock
Home listing (NASDAQ) of PharmaCyte Biotech, Inc.
Follow PharmaCyte Biotech, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PMCB
$3.98 USD -0.58 (-12.8%)
Close on Nov 20, 2026
- Day range
- $3.98 – $4.53 USDNov 20, 2026
- Volume
- 16,203 sharesNov 20, 2026
- Market cap
- $2.25M USDAt the close on Nov 20, 2026 · price × 565,034 shares outstanding
- 52-week range
- $3.98 – $28.69 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $25,864 USDMedian day 271 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PMCB · Home | $3.975 USD | -0.585 (-12.8%) | 16,203 | $4.48 | $4.53 | $3.975 | $4.56 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PMCB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.975 | -0.585 | -12.8% | $4.48 | $4.53 | $3.975 | 16,203 | |
| $4.56 | -0.81 | -15.1% | $5.37 | $5.37 | $4.56 | 21,319 | |
| $5.37 | -0.05 | -0.9% | $5.512 | $5.512 | $5.35 | 6,331 | |
| $5.42 | -0.15 | -2.7% | $5.60 | $5.855 | $5.40 | 7,379 | |
| $5.57 | -1.11 | -16.6% | $6.65 | $6.65 | $5.46 | 57,989 | |
| $6.68 | -0.958 | -12.5% | $8.175 | $8.175 | $6.50 | 127,077 | |
| $7.638 | +0.057 | +0.8% | $7.408 | $7.961 | $6.842 | 1,137 | |
| $7.581 | -0.059 | -0.8% | $5.928 | $8.235 | $4.691 | 3,515 | |
| $7.64 | -0.093 | -1.2% | $7.648 | $7.874 | $7.222 | 321 | |
| $7.733 | +0.893 | +13.1% | $6.821 | $8.235 | $6.821 | 507 | |
| $6.84 | -0.289 | -4.1% | $6.908 | $7.203 | $6.821 | 104 | |
| $7.129 | -0.11 | -1.5% | $7.334 | $7.655 | $6.365 | 565 | |
| $7.239 | +0.777 | +12.0% | $6.403 | $7.999 | $6.403 | 2,517 | |
| $6.462 | +0.566 | +9.6% | $6.012 | $6.464 | $6.012 | 176 | |
| $5.896 | +0.156 | +2.7% | $5.89 | $6.08 | $5.89 | 113 | |
| $5.74 | -0.57 | -9.0% | $6.365 | $6.46 | $5.74 | 337 | |
| $6.31 | -0.049 | -0.8% | $6.646 | $7.216 | $6.27 | 114 | |
| $6.359 | -0.16 | -2.4% | $6.462 | $7.212 | $6.359 | 49 | |
| $6.519 | -0.133 | -2.0% | $6.603 | $7.098 | $6.46 | 192 | |
| $6.652 | -0.097 | -1.4% | $7.076 | $7.592 | $6.555 | 32 | |
| $6.749 | +0.099 | +1.5% | $6.595 | $7.596 | $6.494 | 124 | |
| $6.65 | +0.051 | +0.8% | $7.04 | $7.04 | $6.519 | 91 | |
| $6.599 | +0.097 | +1.5% | $6.527 | $6.965 | $6.527 | 141 | |
| $6.502 | +0.004 | +0.1% | $6.462 | $7.038 | $6.462 | 69 | |
| $6.498 | +0.034 | +0.5% | $6.462 | $7.068 | $6.462 | 73 | |
| $6.464 | -0.327 | -4.8% | $6.65 | $6.865 | $6.462 | 91 | |
| $6.791 | +0.169 | +2.6% | $6.498 | $6.886 | $6.498 | 150 | |
| $6.622 | -0.141 | -2.1% | $6.783 | $7.112 | $6.462 | 112 | |
| $6.762 | -0.175 | -2.5% | $6.821 | $7.106 | $6.65 | 170 | |
| $6.937 | -0.747 | -9.7% | $7.448 | $7.524 | $6.819 | 336 | |
| $7.684 | +0.133 | +1.8% | $7.756 | $7.883 | $7.429 | 259 | |
| $7.551 | -0.156 | -2.0% | $7.739 | $8.016 | $7.344 | 593 | |
| $7.706 | -0.319 | -4.0% | $7.923 | $8.018 | $7.621 | 270 | |
| $8.026 | +0.614 | +8.3% | $7.41 | $8.44 | $7.41 | 643 | |
| $7.412 | -0.19 | -2.5% | $7.60 | $7.782 | $7.317 | 204 | |
| $7.602 | -0.072 | -0.9% | $7.754 | $8.071 | $7.602 | 124 | |
| $7.674 | -0.127 | -1.6% | $7.94 | $8.33 | $7.632 | 229 | |
| $7.801 | -0.16 | -2.0% | $7.98 | $8.356 | $7.754 | 536 | |
| $7.961 | -0.017 | -0.2% | $8.132 | $8.487 | $7.961 | 307 | |
| $7.978 | -0.401 | -4.8% | $8.322 | $8.322 | $7.805 | 394 | |
| $8.379 | -0.293 | -3.4% | $8.569 | $9.006 | $8.36 | 1,110 | |
| $8.672 | +0.53 | +6.5% | $8.132 | $8.848 | $8.132 | 800 | |
| $8.142 | -0.57 | -6.5% | $8.36 | $8.702 | $8.012 | 668 | |
| $8.712 | +0.146 | +1.7% | $8.442 | $8.782 | $8.44 | 272 | |
| $8.565 | -0.169 | -1.9% | $8.74 | $8.74 | $8.362 | 278 | |
| $8.734 | +0.678 | +8.4% | $7.828 | $9.074 | $7.769 | 1,304 | |
| $8.056 | +0.148 | +1.9% | $7.809 | $8.512 | $7.623 | 1,281 | |
| $7.908 | +0.644 | +8.9% | $7.125 | $9.50 | $7.125 | 9,357 | |
| $7.264 | -0.184 | -2.5% | $7.222 | $7.887 | $6.344 | 2,880 | |
| $7.448 | -1.106 | -12.9% | $8.389 | $8.586 | $6.65 | 1,653 | |
| $8.554 | +0.15 | +1.8% | $8.366 | $8.892 | $8.174 | 136 | |
| $8.404 | -0.627 | -6.9% | $9.137 | $9.498 | $8.231 | 337 | |
| $9.031 | -0.26 | -2.8% | $9.308 | $9.472 | $8.841 | 185 | |
| $9.291 | +0.047 | +0.5% | $9.31 | $9.876 | $9.12 | 638 | |
| $9.244 | -0.091 | -1.0% | $9.50 | $9.517 | $9.225 | 126 | |
| $9.335 | +0.201 | +2.2% | $9.302 | $9.783 | $9.122 | 380 | |
| $9.133 | -0.141 | -1.5% | $9.215 | $9.473 | $8.934 | 134 | |
| $9.274 | -0.243 | -2.6% | $9.31 | $9.671 | $9.122 | 153 | |
| $9.517 | -0.268 | -2.7% | $9.88 | $10.07 | $9.12 | 292 | |
| $9.785 | -0.479 | -4.7% | $10.12 | $10.12 | $9.584 | 231 | |
| $10.26 | -0.006 | -0.1% | $10.46 | $10.74 | $10.09 | 158 | |
| $10.27 | +0.017 | +0.2% | $10.41 | $10.47 | $9.882 | 204 | |
| $10.25 | +0.277 | +2.8% | $9.88 | $10.26 | $9.709 | 189 | |
| $9.975 | -0.152 | -1.5% | $10.13 | $10.26 | $9.88 | 172 | |
| $10.13 | +0.355 | +3.6% | $9.842 | $10.26 | $9.795 | 257 | |
| $9.772 | -0.344 | -3.4% | $10.09 | $10.12 | $9.584 | 257 |
Splits
3 splits since 2003 · NASDAQ:PMCB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-19 | Consolidation | |
| 1-for-1500 | Consolidation | |
| 3-for-1 | Split |
- Ticker
- NASDAQ:PMCB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
PharmaCyte Biotech Reports Strong Cash and Asset Position
Latest news
PharmaCyte Biotech Reports Strong Cash and Asset Position
Nov 13, 2026
Closed $6.68 (-12.5%) on Nov 13, 2026
PharmaCyte Biotech, Inc. Announces Reverse Stock Split
Nov 11, 2026
Closed $7.58 (-0.8%) on Nov 11, 2026
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
Nov 25, 2025
Closed $16.91 (+36.9%) on Nov 25, 2025
PharmaCyte Biotech, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 3 in the last 12 months · 108 in all · newest Nov 13, 2026 · oldest 2019
- Decks
- 4 decks · latest Mar 9, 2022
Where PharmaCyte Biotech, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PMCB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PMCB | BOATS | United States | USD |
Valuation
Price/book 0.1× against a median of 0.5×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- −$15.59M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.97
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.22M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| Median of the others | US$2.33M | US$1.00M | 0.7× | 1.5× | 0.5× | −301.9% | 0.0× | 1.42 |
Team and board
Officers
| Officer | Role |
|---|---|
| Joshua N. Silverman | Interim Chief Executive Officer, President, and Director |
| Carlos A. Trujillo | Chief Financial Officer |
| José Iglesias | Consulting Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Jonathan L. Schechter | Director |
| Joshua N. Silverman | Interim Chief Executive Officer, President, and Director |
| Michael M. Abecassis | Director |
| Robert Weinstein | Director |
| Wayne R. Walker | Director |
Events
- Next results
- Dec 17, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Sep 14, 2026 | −15.1% |
| Q4 2026 | Jul 29, 2026 | +1.7% |
| Q3 2026 | Mar 17, 2026 | −0.1% |
| Q2 2026 | Dec 31, 2025 | +2.5% |
| Q1 2026 | Sep 15, 2025 | −2.9% |
| Q4 2025 | Jul 2, 2025 | −2.6% |
| Q3 2025 | Mar 17, 2025 · Before open | 0.0% |
| Q2 2025 | Dec 13, 2024 · After close | −1.7% |
| Q1 2025 | Aug 13, 2024 · After close | +2.2% |
| Q4 2024 | Jul 29, 2024 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | Mar 18, 2024 · After close | +6.5% |
| Q2 2024 | Dec 15, 2023 · After close | +0.9% |
| Q1 2024 | Sep 18, 2023 · Before open | −0.4% |
| Q4 2023 | Jul 31, 2023 · After close | +0.4% |
| Q3 2023 | Mar 16, 2023 · After close | +0.7% |
| Q2 2023 | Dec 14, 2022 · After close | +3.1% |
| Q1 2023 | Sep 14, 2022 · After close | +1.9% |
| Q4 2022 | Jul 28, 2022 · After close | 0.0% |
| Q3 2022 | Mar 15, 2022 · After close | −0.5% |
| Q2 2022 | Dec 14, 2021 · After close | +6.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2022) | Investor deck | 44 slides | Mar 9, 2022 |
| Investor Presentation (September 2021) | Investor deck | 40 slides | Sep 10, 2021 |
| BIO International Convention 2017 | Conference | 21 slides | June 2017 |
| Investor Presentation (May 2016) | Investor deck | 34 slides | May 29, 2016 |
Financings
| Raise | Date |
|---|---|
| Private placement of series C convertible preferred stock and common stock purchase warrants Closed: US$7M raised · US$1,000 a share · Warrants at US$1 for 60 months · GP Nurmenkari Inc. Dealers: GP Nurmenkari Inc. (lead) Use of proceeds: Strengthen balance sheet to support ongoing business initiatives and strategic growth opportunities | Aug 20, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 391.3K | 438.4K | 407.4K | 468.5K | 690.9K | 916.2K | 301.2K | 460.1K | 2.00M | 1.18M |
| Operating income | -6.85M | -4.38M | -8.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M |
| Interest expense | 0 | 509 | 3.05K | 453 | 0 | 0 | 1.54K | |||
| Income before tax | -19.4M | 30.7M | ||||||||
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -19.4M | 30.7M | 333.8K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M |
| Earnings per share, basic | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | -4.23 | 0.00 | -0.01 | -0.01 |
| Earnings per share, diluted | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.45 | -4.23 | 0.00 | -0.01 | -0.01 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 18.6M | 15.2M | 50.2M | 68.0M | 85.4M | 2.20M | 894.9K | 515.3K | 1.06M | 3.46M |
| Short-term investments | 254.0K | 366.3K | 0 | |||||||
| Current assets | 37.4M | 22.4M | 50.4M | 68.1M | 85.5M | 2.28M | 1.04M | 653.4K | 1.28M | 3.54M |
| Total assets | 46.8M | 55.2M | 59.9M | 73.3M | 90.6M | 7.40M | 6.17M | 5.78M | 6.41M | 8.67M |
| Accounts payable | 271.1K | 399.2K | 389.4K | 128.3K | 205.4K | 172.3K | 185.8K | 121.9K | 352.6K | 365.6K |
| Current liabilities | 826.4K | 2.91M | 7.42M | 586.6K | 704.4K | 724.8K | 1.03M | 742.9K | 644.2K | 580.2K |
| Total liabilities | 11.8M | 3.28M | 20.4M | 586.6K | 704.4K | 724.8K | 1.08M | 742.9K | 644.2K | 580.2K |
| Shareholders' equity | 33.3M | 51.9M | 27.6M | 72.7M | 89.9M | 6.68M | 5.09M | 5.04M | 5.77M | 8.09M |
| Shares outstanding | 10.7M | 6.80M | 8.04M | 16.8M | 20.7M | 1.59M | 1.09M | 1.19B | 1.01B | 905.3M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.15M | -2.98M | -2.15M | -3.79M | -4.12M | -3.33M | -2.34M | -2.88M | -5.08M | -3.34M |
| Cash from investing | 2.00M | -7.00M | -5.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from financing | 6.58M | -25.0M | -10.7M | -13.6M | 87.3M | 4.64M | 2.73M | 2.34M | 2.68M | 4.88M |
| Share buybacks | -401.6K | -2.54M | -28.2M | -13.6M | 0 | |||||
| Change in cash | 3.43M | -35.0M | -17.9M | -17.4M | 83.2M | 1.31M | 379.6K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Sep 14, 2026 | Quarterly report | SEC |
| 10-K · Annual report | Jul 29, 2026 | Annual report | SEC |
| 4/A · Change in ownership, amended | Jul 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Mar 17, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Mar 9, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 9, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 27, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 18, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Dec 15, 2025 | Explanation request | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Nov 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 31, 2025 | Management or board change | SEC |
| DEF 14A · Proxy statement | Oct 6, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Sep 24, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Sep 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 23, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 16, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | Sep 5, 2025 | Acquisition or disposal | SEC |
| D | Sep 3, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 18, 2025 | Material contract | SEC |
| 10-K · Annual report | Aug 8, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Jul 29, 2025 | Explanation request | SEC |
| 8-K · Current report | Apr 24, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Mar 17, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Mar 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Dec 13, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Dec 4, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Sep 16, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Sep 16, 2024 | Explanation request | SEC |
| 10-K · Annual report | Aug 13, 2024 | Annual report | SEC |
| NT 10-K · Late filing notice | Jul 29, 2024 | Explanation request | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 30, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | May 30, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 23, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | May 1, 2024 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Mar 27, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 27, 2024 | Annual report | SEC |
| 10-Q · Quarterly report | Mar 18, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Dec 15, 2023 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Nov 28, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 24, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| SC 13D · Big-stake notice | Nov 22, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 15, 2023 | Material contract | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 2, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 27, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Sep 21, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Sep 18, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Sep 15, 2023 | Explanation request | SEC |
| S-3/A · Registration statement, amended | Sep 11, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 7, 2023 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Aug 4, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Aug 4, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 4, 2023 | Current report | SEC |
| 10-K · Annual report | Jul 31, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 31, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 19, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 18, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jun 26, 2023 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 16, 2023 | Big-stake notice | SEC |
| SC TO-I/A | Jun 15, 2023 | Acquisition or disposal | SEC |
| S-3 · Registration statement | Jun 9, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Jun 5, 2023 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Jun 5, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 30, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 25, 2023 | Meeting notice | SEC |
| SC 13G · Big-stake notice | May 19, 2023 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | May 19, 2023 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | May 12, 2023 | Big-stake notice | SEC |
| SC TO-I | May 11, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | May 11, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Mar 16, 2023 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Dec 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2022 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Dec 14, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 25, 2022 | Meeting notice | SEC |
| 8-K · Current report | Nov 18, 2022 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 16, 2022 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Nov 15, 2022 | Meeting notice | SEC |
| 8-K · Current report | Nov 7, 2022 | Management or board change | SEC |
| SC 13G · Big-stake notice | Oct 20, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Oct 14, 2022 | Management or board change | SEC |
| 8-K · Current report | Oct 7, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Sep 14, 2022 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Aug 24, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 23, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2022 | Material contract | SEC |
| DEFA14A · Additional proxy material | Aug 15, 2022 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 15, 2022 | Big-stake notice | SEC |
| 10-K · Annual report | Jul 28, 2022 | Annual report | SEC |
| 8-K · Current report | Jul 28, 2022 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 28, 2022 | Meeting notice | SEC |
| DFAN14A | Jul 28, 2022 | Other filings | SEC |
| PREC14A | Jul 26, 2022 | Other filings | SEC |
| 8-K · Current report | Jul 21, 2022 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 21, 2022 | Meeting notice | SEC |
| 8-K · Current report | Jul 19, 2022 | Current report | SEC |
| DEFA14A · Additional proxy material | Jul 19, 2022 | Meeting notice | SEC |
| DFAN14A | Jul 11, 2022 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 11, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jul 11, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | Jul 11, 2022 | Meeting notice | SEC |
| DFAN14A | Jul 5, 2022 | Other filings | SEC |
| DFAN14A | Jun 23, 2022 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 23, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Jun 15, 2022 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 15, 2022 | Meeting notice | SEC |
| 8-K · Current report | Jun 6, 2022 | Current report | SEC |
| 8-K · Current report | Apr 13, 2022 | Management or board change | SEC |
| 3 · Initial statement of ownership | Apr 11, 2022 | Insider trade | SEC |
| 8-K · Current report | Apr 5, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | Mar 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Mar 9, 2022 | Current report | SEC |
| 8-K · Current report | Feb 28, 2022 | Current report | SEC |
| 8-K · Current report | Feb 17, 2022 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 4, 2022 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Dec 14, 2021 | Quarterly report | SEC |
| 424B3 · Prospectus | Nov 19, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 18, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 15, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2021 | Other filings | SEC |
| S-3 · Registration statement | Nov 5, 2021 | Offer document | SEC |
| SC 13D · Big-stake notice | Nov 4, 2021 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Sep 14, 2021 | Quarterly report | SEC |
| 8-K · Current report | Sep 9, 2021 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 3, 2021 | Insider trade | SEC |
| D | Aug 31, 2021 | Other filings | SEC |
| 3 · Initial statement of ownership | Aug 31, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2021 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 30, 2021 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 30, 2021 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 23, 2021 | Offer document | SEC |
| 8-K · Current report | Aug 23, 2021 | Material contract | SEC |
| 3 · Initial statement of ownership | Aug 20, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2021 | Insider trade | SEC |
| S-3MEF | Aug 19, 2021 | Other filings | SEC |
| 8-K · Current report | Aug 11, 2021 | Material contract | SEC |
| CERT · Exchange's certificate of listing | Aug 10, 2021 | Other filings | SEC |
| 10-K · Annual report | Aug 10, 2021 | Annual report | SEC |
| 424B5 · Prospectus | Aug 10, 2021 | Offer document | SEC |
| 8-K · Current report | Aug 2, 2021 | Current report | SEC |
| 424B5 · Prospectus | Aug 2, 2021 | Offer document | SEC |
This page holds 200 of 476 filings. Open Filings
Cap table
Built by 6ix from PharmaCyte Biotech, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 565,034
- Fully diluted
- 565,034
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 565,034 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.00 · expire about Aug 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 565,034 |
| Nov 13, 2026 | |
| Nov 11, 2026 | |
| Nov 11, 2026 | |
| Nov 11, 2026 | 10,755,649 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Weinstein Other companies: Petros Pharmaceuticals Inc (Chief Accounting Officer · Since at least Jun 18, 2026); TAO Synergies Inc. (Chief Financial Officer · Since at least Jun 4, 2021); XWELL, Inc. (Director & Chair of Audit Committee · Since at least Feb 3, 2020); TaoWeave, Inc. (Director · May 29, 2023 – May 29, 2023 · Past); Neurotrope Inc (See Remarks · Nov 13, 2015 – Dec 1, 2020 · Past) | Director · Since at least Nov 14, 2022 |
| Wayne Walker Other companies: Pitney Bowes Inc. (Board Member · Since at least Sep 12, 2025); Outdoor Holding Company (Director · Since at least Nov 3, 2022); Fabric.AI, Inc. (Director · Since at least Dec 17, 2020); Petros Pharmaceuticals Inc (Board of Directors · Since at least Dec 1, 2020); Wrap Technologies, Inc. (Director · Nov 14, 2018 – Jul 7, 2023 · Past) | Director · Since at least Dec 28, 2022 |
| Jonathan L. Schechter Other companies: TaoWeave, Inc. (Director · Since at least May 29, 2023); TAO Synergies Inc. (Director · Since at least Jun 4, 2021); Neurotrope Inc (Director · Mar 15, 2019 – Dec 1, 2020 · Past) | Director · Since at least Aug 15, 2022 |
| Joshua N. Silverman Other companies: Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Nov 5, 2026); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 30, 2026); TAO Synergies Inc. (Executive Chairman · Since at least Sep 22, 2025) | Interim Chief Executive Officer, President, and Director · Since at least Nov 5, 2026 |
| Daniel Allen Other companies: SharpSpring Inc (Director · Apr 23, 2019 – Jul 24, 2019 · Past) | Director · Aug 15, 2022 – Dec 28, 2022 · Past |
| Thomas C K Yuen Other companies: SRS Labs Inc (CEO, Chairman of the Board, Director · Jun 8, 2010 – Jul 20, 2012 · Past) | Director · Aug 10, 2021 – Aug 10, 2021 · Past |
| Carlos A. Trujillo | Chief Financial Officer · Since at least Nov 5, 2026 |
| Daniel Stuart Farb | Director · Aug 15, 2022 – Dec 28, 2022 · Past |
| José Iglesias | Consulting Chief Medical Officer · Since at least Nov 5, 2026 |
| Michael M. Abecassis | Director · Since at least Aug 10, 2021 |
All 12 people
| Person | Seat |
|---|---|
| Raymond CF Tong | Director · Aug 10, 2021 – Aug 10, 2021 · Past |
| Thomas Liquard | Director · Aug 10, 2021 – Aug 10, 2021 · Past |
Log in to ask 6ix AI your own questions about PharmaCyte Biotech, Inc.